- Pfizer expects to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid.
- But the drugmaker posted mixed fourth-quarter results, beating on earnings but missing on revenue.
- Pfizer forecasts $98 billion to $102 billion in sales for 2022, and adjusted earnings per share of $6.35 to $6.55.
- On an unadjusted basis, fourth-quarter profit soared more than fourfold to $3.39 billion.
www.cnbc.com/2022/02/08/covid-pfizer-pfe-earnings-q4-2021.html
(Reuters) – Pfizer Inc said on Tuesday it expects 2022 sales of its COVID-19 vaccine and antiviral pill to top $54 billion, but that fell short of lofty Wall Street estimates and its shares were off about 3%.
Still, Chief Executive Albert Bourla said final sales for its oral COVID-19 antiviral, Paxlovid, could be “way bigger” than what Pfizer has forecast since its current outlook only included contracts that have been or are close to being signed.
Pfizer currently expects $22 billion in 2022 sales of the treatment, compared with Wall Street estimates of $22.88 billion.
“Clearly, this is only a fraction of the 120 million treatments that we are right now preparing to manufacture” this year, Bourla told analysts on a conference call.
Pfizer Quietly Adds Warnings As Devastating Safety Data Is Set To Be Released
Two weeks ago, the FDA begged a Texas judge to delay production on the first monthly batch of 55,000 pages of Covid-19 vaccine data submitted to the agency by Pfizer. Originally, the agency was set to produce just 500 pages-per-month.
Now, Pfizer — which just forecast $54 billion in Covid-related sales in 2022, appears to be anticipating some bad news, as evidenced by several redline changes in their Q4 earnings releases.
As Rubicon Capital’s Kelly Brown notes on Twitter, the changes center around disclosures of unfavorable safety data.
For example, in Q4 they added: “or further information regarding the quality…